* Trevena Inc TRVN.OQ reported a quarterly adjusted loss
of
$1.06 per share for the quarter ended in December, lower than
the same quarter last year, when the company reported EPS of -73
cents. The mean expectation of two analysts for the quarter was
for a loss of 38 cents per share. Wall Street expected
results to range from -52 cents to -24 cents per share.
* Revenue was $-81.00 thousand; analysts expected $143.50
thousand.
* Trevena Inc's reported EPS for the quarter was a loss of
$1.06.
* The company reported a quarterly loss of $16.53 million.
* Trevena Inc shares had held steady so far this quarter and
lost 36.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 59.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Trevena Inc is
$6.50
This summary was machine generated from LSEG data April 1 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.38 -1.06 Missed
Sep. 30 2023 -0.15 -0.57 Missed
Jun. 30 2023 -1.05 -0.69 Beat
Mar. 31 2023 -0.98 -0.81 Beat